Deals wrap: Genzyme addresses investors

December 20, 2010

A sign on the fence marks Genzyme's plant in the Boston, Massachsetts neighborhood of Allston March 24, 2010.  REUTERS/Brian Snyder Genzyme, which is fighting off a hostile $18.5 billion bid from Sanofi-Aventis, will on Monday take another stab at persuading investors that its experimental multiple sclerosis drug is worth more than Sanofi’s projections.

AT&T said it agreed to buy spectrum licenses in the Lower 700 MHz frequency band from Qualcomm for $1.93 billion, to provide advanced 4G mobile broadband.

Sara Lee has been in talks to sell itself to Brazilian meat producer JBS, but the pair are at odds over price and it is unclear if a deal can be reached, a source familiar with the situation said on Sunday.

“Groupon has built a new channel into the heart of the the world’s economic activity: Small businesses,” writes John Battelle in Searchblog.

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see